Biohaven Ltd.
As of Oct 22, 2026, Biohaven is in Stage 3, the topping phase, now in week 5 (since Sep 21, 2026). It closed at $14.69, 18.9% below its 52-week high and above its 200-day average, which is rising.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is BHVN early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
BHVN among Biotechnology239th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …239 | BHVN | Stage 3 · wk 5 | 41 | +7.5% |
Biohaven: quick answers
What stage is Biohaven in?
As of Oct 22, 2026, Biohaven (BHVN) is in Stage 3, the topping phase. It entered Stage 3 on Sep 21, 2026 and is in week 5. What the four stages mean
Is Biohaven in an uptrend?
Its uptrend has stalled. Biohaven is in Stage 3, the topping phase that follows an advance. It trades 21.2% above its 200-day average, which is rising.
How far is Biohaven from its 52-week high?
Biohaven closed at $14.69 on Oct 22, 2026, 18.9% below its 52-week high of $18.11. Its 52-week low is $7.79.
How has Biohaven performed over the past year?
As of Oct 22, 2026, Biohaven is down 17.1% over the past year and up 35.5% so far in 2026.
Which sector and industry is Biohaven in?
Biohaven is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.